TAKE IT DOWN Act Tools to Address Known Exploitation by Immobilizing Technological Deepfakes On Websites and Networks Act

Honor Our Living Donors ActThis bill modifies certain criteria used to determine eligibility under the Living Organ Donation Reimbursement Program, which reimburses organ donors for certain incidental expenses related to organ donation (e.g., travel expenses). The bill specifies that the organ recipient's income may not be considered in determining whether an organ donor may be reimbursed under the program. (Currently, an organ recipient's income may not be greater than 350% of the federal poverty guidelines.) Additionally, under the bill, organ donors may be reimbursed regardless of whether the organ recipient pays them (or could be expected to pay them) for their expenses.The Department of Health and Human Services must report on whether the program adequately covers the expenses of organ donors, and if not, the amount of necessary funding. 

Cover Outstanding Vulnerable Expansion-eligible Residents Now Act or the COVER Now Act This bill establishes a demonstration program to allow local governments to provide health benefits to the Medicaid expansion population in states that have not expanded Medicaid. Under the program, local governments may provide coverage for individuals who are newly eligible for Medicaid under the Patient Protection and Affordable Care Act (i.e., the Medicaid expansion population) for a maximum of 10 years, or until their respective states expand Medicaid. The bill provides a 100% federal matching rate for the first three years of program participation. The bill prohibits states from taking certain actions against participating localities, such as withholding funding, increasing taxes, or restricting provider participation. States that violate these requirements are subject to certain funding penalties.

Reinforcing the Grid Against Extreme Weather Act of 2025

Ensuring Accurate and Complete Abortion Data Reporting Act of 2025This bill requires states, as a condition of federal payment under Medicaid for family planning services, to report certain abortion data to the Centers for Disease Control and Prevention (CDC). (Currently, reporting is voluntary.) The CDC must develop standardized questions for states with respect to specified variables (e.g., maternal demographics and methods of abortion).

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

Health Care Providers Safety Act of 2025This bill authorizes the Department of Health and Human Services to award grants to health care providers for security services and other expenses related to physical security and cybersecurity.

REDUCE Act Responsive Energy Demand Unlocks Clean Energy Act

SAFE Grilling Act Strengthening Awareness and Funding Education for Grilling Act

Close the Medigap Act of 2025This bill (1) expands guaranteed issue rights with respect to Medigap policies (Medicare supplemental health insurance policies), (2) eliminates certain limitations on Medigap policies for newly eligible Medicare beneficiaries, and (3) modifies other provisions related to Medigap policies. (Guaranteed issue rights require that a policy be offered to any eligible applicant without regard to health status.)

Doctor Knows Best Act of 2025

Standing with Moms ActThis bill requires the Department of Health and Human Services (HHS) to disseminate information about pregnancy-related resources, including information about abortion risks and alternatives.Specifically, HHS must create a public website called life.gov that lists such resources that are available through federal, state, and local governments and private entities.Additionally, HHS must create on its existing website a portal that provides a user, based on the user's responses to a series of questions, tailored information about pregnancy resources available in the user's zip code and risks related to abortion. HHS must develop a plan to conduct follow-up outreach to users of the portal (if the user consents to the outreach). States must recommend resources that meet criteria set by HHS for inclusion in the portal. HHS may award grants to states to establish or support a system that aggregates resources to include in the portal.Further, the Health Resources and Services Administration must share information about the new website and portal through the National Maternal Mental Health Hotline.HHS must also ensure that the new website and hotline are available to families who speak languages other than English.The new website, portal, and hotline may not include resources provided by entities that (1) perform, induce, refer for, or counsel in favor of abortions; or (2) financially support such entities.The bill also requires HHS to report on traffic to the new website and portal, gaps in services available to pregnant and postpartum individuals, and related matters.

Spectrum Pipeline Act of 2025

Maximizing Israel-U.S. Research Advancement and Collaborative Leadership in Emerging Medical Technology Act of 2025 or the MIRACLE Medical Technology Act of 2025This bill requires the Department of Health and Human Services (HHS) to implement a program for the United States and Israel to collaborate on developing and delivering health care products and services. The program must include coordinated activities in specified areas, including research and development, use of innovative technology, intellectual property protection, regulatory harmonization, disease prevention, and biological product manufacturing. The bill authorizes HHS to establish a joint United States-Israel Health Care Collaboration Center in the United States to leverage existing expertise for advancing the program’s purposes.

Support And Value Expectant Moms and Babies Act of 2025 or the SAVE Moms and Babies Act of 2025This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)